Pathogenesis, Prophylaxis, and Treatment of Candida auris

Abstract

Candida auris poses a serious threat to infection control and patient care since it can produce invasive infections that have a high fatality rate, has been linked to outbreaks in hospital environments, and is typically resistant to several antifungal medications. Since its first description in 2009, six clades have been described. The emerging fungal pathogen possesses adhesins that allow it to adhere to host tissues and medical devices, can form biofilms, produces various hydrolytic enzymes, employs several strategies to evade host immune responses, and exhibits high genetic diversity, which may contribute to its ability to adapt to different environmental conditions and evade host defenses. C. auris is very resistant to various disinfectants and may be difficult to detect.

Navigating the Maze: Exploring Non-Oncological Complexities in Non-Small-Cell Lung Cancer

“…Infections, lung metastases, chronic pulmonary bleeding, pneumoconiosis, deposition illnesses, and idiopathic conditions like pulmonary alveolar microlithiasis are among the conditions that can cause diffusely distributed smaller calcified nodules [13,22]. Additionally, calcified lesions may also include Histoplasma capsulatum, Coccidioides immitis, tuberculosis, lung cancer, condrosarcoma, osteosarcoma, or others [22,25]. This underscores the necessity for a comprehensive evaluation and correlation with clinical and pathological findings to accurately determine the underlying etiology of calcified nodules in the lungs.…”

The Potential of Dutasteride for Treating Multidrug-Resistant Candida auris Infection

“…As a result, the incidence and prevalence of C. auris have been increasing among immunocompromised patients and those under long-term hospitalization [ 1 , 3 , 8 , 9 , 10 ]. Owing to its high mortality rate, tendency to cause nosocomial invasive infections, and multidrug-resistant nature, C. auris poses a serious global public health concern [ 11 , 12 , 13 , 14 ]. C. auris has been reported to have a high rate of intrinsic resistance to antifungal treatments such as amphotericin B and fluconazole, but few countries have reported acquired echinocandin resistance [ 15 , 16 ].…”